Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caspofungin vs Liposomal Amphotericin B in Pediatric Febrile Neutropenia
NCT00082537Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Apr 2004
- Primary completion
- Oct 2006
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of caspofungin in febrile neutropenia (FN) (2 arms), sponsored by Merck & Co. Primary endpoint: Proportion of patients reporting one or more clinical and/or laboratory drug-related adverse experience(s). Started Apr 2004; status: completed.
02
Drugs
caspofungin
03
Conditions
febrile neutropenia (FN)
Beyond the preview
Go deeper on NCT00082537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00082537.